NOVELIX Q1 FY27 results at a glance
NOVELIX PHARMACEUTICALS LIMITE Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹36.91 cr |
|---|
| Revenue YoY | +65.2% |
|---|
| Operating profit | ₹1.23 cr |
|---|
| Operating margin | 3.3% |
|---|
| Net profit | ₹1.18 cr |
|---|
| Net profit YoY | +1001.8% |
|---|
| Net profit QoQ | +29.3% |
|---|
| Net margin | 3.2% |
|---|
| Basic EPS | ₹0.49 |
|---|
| TTM revenue | ₹147 cr |
|---|
| TTM net profit | ₹3.63 cr |
|---|
| TTM net margin | 2.5% |
|---|
NOVELIX Q1 FY27 results: what the numbers say
NOVELIX PHARMACEUTICALS LIMITE (NOVELIX) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹36.91 cr and a net profit of ₹1.18 cr, translating into earnings per share of ₹0.49.
Compared with the same quarter a year earlier, revenue grew sharply by +65.2% and net profit grew sharply by +1001.8%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹1.23 cr, an operating margin of 3.3% versus 0.8% a year ago — a gain of 2.6 percentage points.
NOVELIX quarter-wise results table
Revenue
₹36.91 cr
+65.2% YoY
Net profit
₹1.18 cr
+1001.8% YoY
Operating profit
₹1.23 cr
+625.8% YoY
NOVELIX PHARMACEUTICALS LIMITE (NOVELIX) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹36.91 cr | ₹1.23 cr | ₹1.18 cr | 3.3% | 3.2% | ₹0.49 | +1001.8% | +29.3% |
| Q4 FY262026-03-31 | ₹25.19 cr | ₹1.23 cr | ₹0.91 cr | 4.9% | 3.6% | ₹0.43 | — | -9.2% |
| Q3 FY262025-12-31 | ₹48.4 cr | ₹1.28 cr | ₹1 cr | 2.7% | 2.1% | ₹0.58 | — | +88.4% |
| Q2 FY262025-09-30 | ₹36.36 cr | ₹0.69 cr | ₹0.53 cr | 1.9% | 1.5% | ₹0.37 | — | +398.2% |
| Q1 FY262025-06-30 | ₹22.35 cr | ₹0.17 cr | ₹0.11 cr | 0.8% | 0.5% | ₹0.09 | — | — |
| TTM (last 4 quarters) | ₹147 cr | ₹4.43 cr | ₹3.63 cr | 3.0% | 2.5% | ₹1.87 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
NOVELIX quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
NOVELIX PHARMACEUTICALS LIMITE quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹36.91 cr | ₹25.19 cr | ₹48.4 cr | ₹36.36 cr | ₹22.35 cr |
|---|
| Total expenses | ₹35.68 cr | ₹23.96 cr | ₹47.12 cr | ₹35.67 cr | ₹22.18 cr |
|---|
| Gross profit | ₹2.05 cr | ₹2.29 cr | ₹1.55 cr | ₹1.17 cr | ₹0.57 cr |
|---|
| Operating profit (EBIT) | ₹1.23 cr | ₹1.23 cr | ₹1.28 cr | ₹0.69 cr | ₹0.17 cr |
|---|
| Operating margin | 3.3% | 4.9% | 2.7% | 1.9% | 0.8% |
|---|
| Interest cost | ₹0.12 cr | ₹0 cr | ₹0 cr | ₹0 cr | ₹0 cr |
|---|
| Profit before tax | ₹1.12 cr | ₹1.23 cr | ₹1.28 cr | ₹0.72 cr | ₹0.17 cr |
|---|
| Tax expense | -₹0.06 cr | ₹0.32 cr | ₹0.28 cr | ₹0.19 cr | ₹0.06 cr |
|---|
| Effective tax rate | -5.7% | 26.0% | 21.7% | 25.8% | 36.8% |
|---|
| Net profit (PAT) | ₹1.18 cr | ₹0.91 cr | ₹1 cr | ₹0.53 cr | ₹0.11 cr |
|---|
| Net profit margin | 3.2% | 3.6% | 2.1% | 1.5% | 0.5% |
|---|
| Basic EPS | ₹0.49 | ₹0.43 | ₹0.58 | ₹0.37 | ₹0.09 |
|---|
| Diluted EPS | ₹0.49 | ₹0.32 | ₹0.58 | ₹0.37 | ₹0.09 |
|---|
NOVELIX results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | +65.2% | — | — | — | — |
|---|
| Revenue QoQ | +46.5% | -47.9% | +33.1% | +62.7% | — |
|---|
| Operating profit YoY | +625.8% | — | — | — | — |
|---|
| Operating profit QoQ | -0.3% | -3.9% | +86.9% | +305.1% | — |
|---|
| Net profit YoY | +1001.8% | — | — | — | — |
|---|
| Net profit QoQ | +29.3% | -9.2% | +88.4% | +398.2% | — |
|---|
| EPS YoY | +444.4% | — | — | — | — |
|---|
| EPS QoQ | +14.0% | -25.9% | +56.8% | +311.1% | — |
|---|
NOVELIX annual results history
Full-year performance for NOVELIX PHARMACEUTICALS LIMITE, useful for reading each quarter in context.
NOVELIX PHARMACEUTICALS LIMITE annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹132 cr | ₹30.72 cr | ₹4.22 cr | ₹1.4 cr |
|---|
| Total expenses | ₹129 cr | ₹30.29 cr | ₹4.35 cr | ₹1.98 cr |
|---|
| Gross profit | ₹5.59 cr | ₹1.14 cr | ₹0.39 cr | ₹0.05 cr |
|---|
| Operating profit (EBIT) | ₹3.48 cr | ₹0.43 cr | -₹0.13 cr | -₹0.57 cr |
|---|
| Operating margin | 2.6% | 1.4% | -3.1% | -40.9% |
|---|
| Interest cost | ₹0.02 cr | ₹0 cr | ₹0 cr | — |
|---|
| Profit before tax | ₹3.4 cr | ₹0.12 cr | ₹0.02 cr | -₹0.06 cr |
|---|
| Tax expense | ₹0.85 cr | ₹0.04 cr | ₹0.01 cr | ₹0 cr |
|---|
| Effective tax rate | 24.9% | 31.5% | 51.0% | -2.5% |
|---|
| Net profit (PAT) | ₹2.56 cr | ₹0.08 cr | ₹0.01 cr | -₹0.06 cr |
|---|
| Net profit margin | 1.9% | 0.3% | 0.2% | -4.3% |
|---|
| Basic EPS | ₹1.21 | ₹0.08 | ₹0.01 | ₹-0.07 |
|---|
| Diluted EPS | ₹1.21 | ₹0.08 | ₹0.01 | ₹-0.07 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹36.91 cr against ₹22.35 cr in Q1 FY26, and ₹25.19 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue grew +46.5%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹35.68 cr, or 96.7% of revenue, with operating profit grew +625.8% year on year.
Margins, tax and profitability
Net profit of ₹1.18 cr works out to a net margin of 3.2% compared with 0.5% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, NOVELIX PHARMACEUTICALS LIMITE reported profit before tax of ₹1.12 cr, a tax charge of -₹0.06 cr (effective rate -5.7%), interest cost of ₹0.12 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹0.91 cr in Q4 FY26 to ₹1.18 cr in Q1 FY27, a change of +29.3%.
Trailing twelve months and annual context
Across the trailing four quarters NOVELIX PHARMACEUTICALS LIMITE has generated revenue of ₹147 cr and net profit of ₹3.63 cr, a trailing net margin of 2.5%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹132 cr with net profit of ₹2.56 cr and EPS of ₹1.21, versus the prior year where revenue grew +330.7% and profit grew +2925.6%.
What to watch in the next NOVELIX quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
NOVELIX PHARMACEUTICALS LIMITE has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
NOVELIX results coverage
No results report published for NOVELIX yet — our desk covers each quarter within minutes of the filing.
NOVELIX quarterly results FAQs
What were NOVELIX PHARMACEUTICALS LIMITE (NOVELIX) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), NOVELIX PHARMACEUTICALS LIMITE reported revenue of ₹36.91 cr and net profit of ₹1.18 cr, a change of +1001.8% year on year on +65.2% revenue growth. EPS stood at ₹0.49.
What is NOVELIX profit margin in Q1 FY27?
NOVELIX PHARMACEUTICALS LIMITE posted a net profit margin of 3.2% and an operating margin of 3.3% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹147 cr and net profit ₹3.63 cr.
Did NOVELIX results beat the previous quarter?
NOVELIX PHARMACEUTICALS LIMITE net profit changed +29.3% quarter on quarter, from ₹0.91 cr in Q4 FY26 to ₹1.18 cr in Q1 FY27.
When are NOVELIX PHARMACEUTICALS LIMITE (NOVELIX) quarterly results?
NOVELIX PHARMACEUTICALS LIMITE has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see NOVELIX latest quarterly results?
Results coverage for NOVELIX will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the NOVELIX stock page.
What is NOVELIX PHARMACEUTICALS LIMITE annual revenue and profit?
For FY26, NOVELIX PHARMACEUTICALS LIMITE reported full-year revenue of ₹132 cr and net profit of ₹2.56 cr, with EPS of ₹1.21.
How many quarterly results has NOVELIX declared recently?
Past results dates for NOVELIX will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
